Effect of auranofin on resorption, prostaglandin synthesis and ultrastructure of bone cells in cultured mouse calvaria. 1989

K Klaushofer, and O Hoffmann, and H Hörandner, and S Karasegh, and N Fratzl-Zelman, and H J Leis, and H Gleispach, and K Koller, and M Peterlik
Ludwig Boltzmann Research Unit for Clinical and Experimental Osteology, University of Vienna Medical School, Austria.

Auranofin (AF) in concentrations between 3 x 10(-7) and 3 x 10(-6) mol/l stimulated bone resorption in cultured neonatal mouse calvariae significantly with 1 x 10(-6) mol/l being most potent. Complete inhibition by 5 x 10(-7) mol/l indomethacin and increased medium concentrations of prostaglandin (PG) E2 and 6-keto-PGF1 alpha after 72 h indicate a PG mediated mechanism. Morphology revealed active osteoclasts. Cytotoxic effects were observed with 3 x 10(-6) and 1 x 10(-5) mol/l AF with osteocytes and osteoblasts being considerably more sensitive than osteoclasts. The latter concentrations inhibited bone resorption stimulated by parathyroid hormone (PTH) 1,25-dihydroxyvitamin D3, PGE2, thrombin and interleukin 1. The stimulatory effect of AF on PG production and subsequent bone resorption could limit its therapeutic usefulness.

UI MeSH Term Description Entries
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D001862 Bone Resorption Bone loss due to osteoclastic activity. Bone Loss, Osteoclastic,Osteoclastic Bone Loss,Bone Losses, Osteoclastic,Bone Resorptions,Loss, Osteoclastic Bone,Losses, Osteoclastic Bone,Osteoclastic Bone Losses,Resorption, Bone,Resorptions, Bone
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001310 Auranofin An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious. Crisinor,Ridaura,Ridauran,SK&F D 39162,SK&F-39162,SK&F 39162,SK&F39162
D012886 Skull The SKELETON of the HEAD including the FACIAL BONES and the bones enclosing the BRAIN. Calvaria,Cranium,Calvarium,Skulls
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

K Klaushofer, and O Hoffmann, and H Hörandner, and S Karasegh, and N Fratzl-Zelman, and H J Leis, and H Gleispach, and K Koller, and M Peterlik
October 1984, European journal of pharmacology,
K Klaushofer, and O Hoffmann, and H Hörandner, and S Karasegh, and N Fratzl-Zelman, and H J Leis, and H Gleispach, and K Koller, and M Peterlik
January 1989, Biochemical and biophysical research communications,
K Klaushofer, and O Hoffmann, and H Hörandner, and S Karasegh, and N Fratzl-Zelman, and H J Leis, and H Gleispach, and K Koller, and M Peterlik
December 1978, Biochemical and biophysical research communications,
K Klaushofer, and O Hoffmann, and H Hörandner, and S Karasegh, and N Fratzl-Zelman, and H J Leis, and H Gleispach, and K Koller, and M Peterlik
October 1985, Clinical science (London, England : 1979),
K Klaushofer, and O Hoffmann, and H Hörandner, and S Karasegh, and N Fratzl-Zelman, and H J Leis, and H Gleispach, and K Koller, and M Peterlik
January 1991, General pharmacology,
K Klaushofer, and O Hoffmann, and H Hörandner, and S Karasegh, and N Fratzl-Zelman, and H J Leis, and H Gleispach, and K Koller, and M Peterlik
July 1985, Proceedings of the National Academy of Sciences of the United States of America,
K Klaushofer, and O Hoffmann, and H Hörandner, and S Karasegh, and N Fratzl-Zelman, and H J Leis, and H Gleispach, and K Koller, and M Peterlik
October 1987, Acta physiologica Scandinavica,
K Klaushofer, and O Hoffmann, and H Hörandner, and S Karasegh, and N Fratzl-Zelman, and H J Leis, and H Gleispach, and K Koller, and M Peterlik
April 1984, The Biochemical journal,
K Klaushofer, and O Hoffmann, and H Hörandner, and S Karasegh, and N Fratzl-Zelman, and H J Leis, and H Gleispach, and K Koller, and M Peterlik
January 1988, Journal of periodontal research,
K Klaushofer, and O Hoffmann, and H Hörandner, and S Karasegh, and N Fratzl-Zelman, and H J Leis, and H Gleispach, and K Koller, and M Peterlik
October 1987, Biochimica et biophysica acta,
Copied contents to your clipboard!